Skip to content
Parakho

Procter & Gamble Health Ltd

NSE PGHLBSE 500126

Q1 FY27, unaudited

Revenue
₹363.71 Cr
Profit after tax
₹96.15 Cr

As filed with the exchange, standalone basis.

Board meeting

Procter & Gamble Health Ltd has given BSE notice of a board meeting on 02 Nov 2026 to consider Q2 FY27 results. Notice · Results calendar

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year ago6M FY26
Revenue from operations363.71+7.37%370.45
Other income3.88−3.72%4.00
Total income367.59+7.24%374.45
Employee benefit expense60.39+7.82%50.86
Finance costs0.14+16.67%0.21
Depreciation & amortisation6.02+10.66%6.17
Total expenses270.27+6.42%241.24
Profit before tax129.12+45.39%133.21
Tax expense32.97+45.69%38.61
Profit after tax96.15+45.29%94.60
Total comprehensive income96.46+47.20%91.67
Earnings per share
Earnings per share, basic₹57.92₹56.99
Earnings per share, diluted₹57.92₹56.99

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

6M FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Procter & Gamble Health Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 33 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.